ADC Therapeutics (NYSE:ADCT) Azioni

ADC Therapeutics

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

ADC Therapeutics SA

TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) today announced it has entered into a definitive agreement to acquire the Simmonds Precision Products, Inc. Business ("Simmonds" or "the Company") of Goodrich Corporation from RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) for approximately $765 million in cash, including certain tax benefits.&nbsp;
Simmonds, headquartered in Vergennes, Vermont, is a leading global designer and manufacturer of fuel &amp; proximity sensing and structural health monitoring solutions for the aerospace and defense end markets. The Company's products are highly engineered, proprietary components with significant aftermarket content and a strong presence across major aerospace and defense platforms. &nbsp;Approximately 40% of Simmonds' revenue is derived from the aftermarket and nearly all of its revenue is generated from proprietary products. Simmonds is expected to generate approximately $350 million in revenue for the calendar year ending December 31, 2025. The Company employs approximately 900 people.
The acquisition is subject to regulatory approvals in the United States and customary closing conditions. The acquisition is expected to be financed through existing cash on hand.
 &nbsp;

News

TransDigm To Acquire Simmonds Precision Products Business Of Goodrich From RTX For ~$765M In Cash, Including Certain Tax Benefits

Hewlett Packard Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) and Juniper Networks, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) reached an agreement with the U.S. Department of Justice (DOJ) on Saturday.
This settlement, subject to court approval, resolves the DOJ&#8217;s lawsuit that challenged HPE&#8217;s acquisition of Juniper and paves the way for the transaction to close.
The acquisition was initially announced in January 2024, where HPE agreed to acquire Juniper in an all-cash transaction for $40.00 per share, valuing Juniper at <a target="_blank" href="https://www.benzinga.com/markets/equities/24/01/36571415/its-official-hewlett-packard-enterprise-buys-juniper-networks-in-a-massive-14b-deal" rel="noreferrer noopener">approximately $14 billion</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45776761/jpmorgan-bullish-on-hewlett-packard-enterprises-future-cites-durable-non-ai-segments-capital-returns" rel="noreferrer noopener">JPMorgan Bullish On Hewlett Packard Enterprise&#8217;s Future, Cites &#8216;Durable&#8217; Non-AI Segments, Capital Returns</a>
The DOJ, in a statement on Saturday, <a target="_blank" href="https://www.justice.gov/opa/pr/justice-department-requires-divestitures-and-licensing-commitments-hpes-acquisition-juniper" rel="noreferrer noopener">said</a>, &#8220;Achieving a result otherwise unavailable through litigation, earlier today, the Justice Department advised the court it had reached a settlement with HPE and Juniper that allows their merger to continue.&#8221;
The agreement satisfies the Department of Justice&#8217;s concerns while maintaining the overall value of the transaction to HPE customers, partners, and shareholders.
As part of the settlement, HPE has <a target="_blank" href="https://www.businesswire.com/news/home/20250628599766/en/HPE-and-Juniper-Networks-Reach-Settlement-With-U.S.-Department-of-Justice" rel="noreferrer noopener">agreed</a> to divest its global Instant On campus and branch business. After closing, HPE will facilitate limited access to Juniper&#8217;s advanced Mist AIOps technology.
Upon closing the deal, HPE and Juniper&#8217;s combined resources are expected to drive faster innovation across networking silicon, systems, and software.
&#8220;This marks an exciting step forward in delivering on a critical customer need, a complete portfolio of modern, secure networking solutions to connect their organizations and provide essential foundations for hybrid cloud and AI,&#8221; said Juniper Networks CEO Rami Rahim. &#8220;We look forward to closing this transaction and turning our shared vision into reality for enterprise, service provider, and cloud customers.&#8221;
For the second quarter, the company reported adjusted earnings per share of 38 cents, beating the consensus estimate of 33 cents. Hewlett posted sales of $7.63 billion, beating the consensus estimate of $7.50 billion, representing a <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/45776696/hewlett-packard-stock-is-trading-higher-wednesday-whats-going-on" rel="noreferrer noopener">6% year-over-year climb</a>.
Price Action: Both HPE and JNPR saw significant gains in premarket trading on Monday. As of the last check on Monday, HPE stock climbed 12.7% to $20.74, while JNPR stock rose 8.42% to $39.92. This surge in share prices follows the announcement of the DOJ settlement, which clears a major hurdle for HPE&#8217;s acquisition of Juniper.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/46166236/palantir-accenture-partner-to-infuse-ai-into-federal-agency-workflows" target="_blank" rel="noreferrer noopener">Palantir, Accenture Partner To Infuse AI Into Federal Agency Workflows</a></li>
</ul>
Photo via Shutterstock

Large Cap

Movers

Tech

General

JNPR

Why Is Hewlett Packard Stock Soaring On Monday?

Offerings

KANZHUN LIMITED Announces Pricing Of 34,500,000 Class A Ordinary Share Offer At HK$66.00 Per Share

HII And C3 AI Partner To Expand Digital Technologies, Apply AI To Accelerate Shipbuilding Throughput At HII's Newport News Shipbuilding And Ingalls Shipbuilding Divisions

Media

CURI

Curiosity University Launches On Amazon Prime Video Channels in Sweden

Asset Sales

ROCK

Gibraltar Industries Board approves Plan To Sell Renewables Business

Management

GAIA

Gaia Appoints Kiersten Medvedich As CEO

Rumble Added To Russell 2000 And Russell 3000 Indexes

Cantor Fitzgerald analyst Jonathan Ruykhaver initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Overweight rating and announces Price Target of $29.

Price Target

Initiation

Analyst Ratings

SAIL

Cantor Fitzgerald Initiates Coverage On SailPoint with Overweight Rating, Announces Price Target of $29

Maxim Group analyst Anthony Vendetti initiates coverage on Laird Superfood (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LSF#AMEX">LSF</a>) with a Buy rating and announces Price Target of $12.

Maxim Group Initiates Coverage On Laird Superfood with Buy Rating, Announces Price Target of $12

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone
Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>, HKEX: 9688))) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis.
Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing.
A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with data readout anticipated in H2 2025.

ZLAB

Zai Lab Says Phase 3 FORTITUDE-101 Clinical Trial Evaluating First-Line Bemarituzumab Plus Chemotherapy Meets Primary Endpoint Of Overall Survival At Pre-Specified Interim Analysis

JMP Securities analyst Andrew Boone maintains Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) with a Market Outperform and raises the price target from $24 to $27.

GRND

JMP Securities Maintains Market Outperform on Grindr, Raises Price Target to $27

Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) reported quarterly losses of $(0.36) per share. This is a 14.29 percent increase over losses of $(0.42) per share from the same period last year.

Earnings

Regencell Bioscience H1 EPS $(0.36) Up From $(0.42) YoY

High-Trend International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>), a Nasdaq-listed global shipping and logistics company, proudly acknowledges the recent correspondence from President Donald J. Trump in response to a letter submitted by Mr. Brian B. Su, the Company's Independent Director and Chairman of the Compensation Committee. In his letter dated June 18, 2025, President Trump expressed appreciation for Mr. Su's views on restoring American strength on the world stage and reaffirmed his administration's commitment to revitalizing American leadership, defense readiness, and strategic dominance in global affairs.

HTCO

High-Trend International Acknowledges President Trump Letter To Board Chairman On Company Affairs

Contracts

BZAI

Blaize Holdings Announces Its AI Platform Will Be Deployed Across Intelligence Surveillance Endpoints; Total Value Of Contracted Purchase Order ~$56M

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">252.8400</td>
<td align="right">2.070</td>
<td align="right">0.82</td>
<td>75.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">108.5600</td>
<td align="right">0.880</td>
<td align="right">0.81</td>
<td>8.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">52.1850</td>
<td align="right">0.245</td>
<td align="right">0.47</td>
<td>330.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.2400</td>
<td align="right">0.120</td>
<td align="right">0.29</td>
<td>3.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">88.0600</td>
<td align="right">0.170</td>
<td align="right">0.19</td>
<td>421</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">134.0100</td>
<td align="right">0.080</td>
<td align="right">0.05</td>
<td>8.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">146.8601</td>
<td align="right">0.070</td>
<td align="right">0.04</td>
<td>5.2K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.80</td>
<td align="right">-0.53</td>
<td align="right">-0.66</td>
<td>67.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.46</td>
<td align="right">-0.09</td>
<td align="right">-0.12</td>
<td>1.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.22</td>
<td align="right">-0.08</td>
<td align="right">-0.10</td>
<td>31.3K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Leading And Lagging Sectors For June 30, 2025

Thomas (Tom) Lee, the Founder of Fundstrat and CIO of Fundstrat Capital, will become Chairman of the Board of Directors effective today.
The transaction was led by MOZAYYX with participation from Founders Fund, Pantera, FalconX, Republic Digital, Kraken, Galaxy Digital, DCG, Diametric Capital, Occam Crest Management, and Thomas Lee.
Upon the closing of the Private Placement, BitMine will advance its treasury strategy on Ethereum.
BitMine Immersion continues to enhance its asset-light and mining business by increasing its existing treasury holdings by over 16x.
LAS VEGAS, June 30, 2025 /PRNewswire/ -- (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) ("BitMine" or the "Company") today announced the pricing and signing of a private placement for the purchase and sale of 55,555,556 shares of common stock (or common stock equivalents in lieu thereof) at a price of $4.50 per share for expected aggregate gross proceeds of approximately $250 million before deducting placement agent fees and other offering expenses (funded in a combination of cash and cryptocurrencies) to implement an Ethereum treasury strategy.
The transaction was led by MOZAYYX with participation from a high quality group of investors including Founders Fund, Pantera, FalconX, Republic Digital, Kraken, Galaxy Digital, DCG, Diametric Capital, Occam Crest Management, and Thomas Lee.
The closing of the offering is expected to occur on or about July 3, 2025, subject to the satisfaction of customary closing conditions, including without limitation, the authorization of the Supplemental Listing Application by the NYSE American. The Company intends to use the net proceeds of the offering to acquire the native cryptocurrency of Ethereum blockchain commonly referred to as "ETH" and contribute the ETH to the Company's treasury operations. ETH will serve as the Company's primary treasury reserve asset.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$ETH

BMNR

BitMine Announces $250M Private Placement Of 55.56M Shares Of Common Stock At $4.50/Share To Launch Ethereum Treasury Strategy; Tom Lee Named Chairman

JMP Securities analyst Jordan Bender maintains Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) with a Market Outperform and raises the price target from $12 to $13.

GENI

JMP Securities Maintains Market Outperform on Genius Sports, Raises Price Target to $13

Acuren Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIC#NYSE">TIC</a>) (the "Company" or "Acuren"), a leading provider of critical asset integrity services, today announced that its registration statement on Form S-4 (the "Registration Statement") filed with Securities and Exchange Commission (the "SEC") in connection with the proposed merger between the Company and NV5 Global, Inc. (("NV5", NASDAQ:<a href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>), was declared effective by the SEC on June 27, 2025. Notice of Acuren's meeting of stockholders to be held in connection with the proposed merger and a definitive joint proxy statement/prospectus is expected to be mailed on or about July 1, 2025, to stockholders of record of the Company as of June 30, 2025. BEFORE MAKING ANY VOTING DECISION, THE COMPANY'S STOCKHOLDERS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING, WHEN AVAILABLE, THE JOINT PROXY STATEMENT/PROSPECTUS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER.&nbsp;

NVEE

Acuren Announces SEC Approval Of Registration Statement For Proposed Merger With NV5 Global

Future Fintech Group Inc. (NASDAQ:&nbsp;<a href="https://www.ftft.com/en/">FTFT</a>), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"),&nbsp;a comprehensive financial and digital technology service provider, today announced certain changes to its management and Board of Directors.
On June 20, 2025, Mr. Ming Yi resigned from his position as the Chief Financial Officer of the Company, Mr. Fuyou Li resigned from his position as the Chairman of the Board and as a member of the Board's audit and compensation committees, and Ms. Ying Li resigned from her positions as a director of the Board and the Vice President of the Company. The resignations of Mr. Ming Yi, Mr. Fuyou Li and Ms. Ying Li from these positions were not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. To fill these vacancies, on June 26, 2025, the Company's Board of Directors appointed Ms. Ting (Alina) Ouyang as a director of the Board and the Chief Financial Officer of the Company, and Mr. David Xu as the Chairman of the Board and as a member of the Board's audit and compensation committees of the Company.

FTFT

Future Fintech Appoints Ting Ouyang As CFO And David Xu As Chairman Of The Board

Press Releases

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

Small Cap

Opinion

The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

ADCT

CTOR

ONCY

OSTX

TEVA

TEVJF

TSX:ONC

RBC Capital

Guggenheim

HC Wainwright & Co.

Stephens & Co.

ADC Telecom

Comments

ADC Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO